Lexatumumab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Lexatumumab (HGS-ETR 2) 是一种人源激动 TRAIL 受体 2 (TRAIL-R2, DR5, APO-2) IgG4κ 型单克隆抗体。Lexatumumab 在恶性间皮瘤中诱导细胞凋亡 (apoptosis)。Lexatumumab 可用于恶性胸膜间皮瘤 (MPM) 研究。

Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research.

Cell Viability Assay Cell Line:Melanoma cell lines Concentration:0.01, 0.1, 1.0 and 10.0 μg/ml Incubation Time:72 h Result:Induced various degrees of cell death in the different cell lines.

Animal Model:FEMX-1 xenografts miceDosage:10 mg/kg, 10 mg/kg+Dacarbazine (62.5 mg/kg once a week, i.p. injection)Administration:i.v., twice a week Result:Increased antitumor effect in vivo when combined with Dacarbazine (HY-B0078). Induced cleavage of livin into its truncated, proapoptotic form, a compound previously shown to accelerate apoptosis.

——

Apoptosis

Apoptosis

Apoptosis

——

——

845816-02-6

143.6 (kDa)

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years